- Parkinsons is diagnosed through skilled observation of specialized neurologists
- Neurologist shortage could turn into public emergency
- EEGs may hold the key to clearer diagnosis of Parkinson’s
Every year an estimated 60,000 people in the United States are diagnosed with Parkinson’s disease (PD) (https://ibn.fm/ca0nb). Symptoms develop slowly, often spanning years, and vary from person to person. For a long time, PD has been diagnosed through the skilled observation of a neurologist, but recent studies suggest the EEG to be a promising diagnostic tool (https://ibn.fm/zCRAz). Brain Scientific (OTCQB: BRSF) is on a mission of modernizing brain diagnostics through cutting-edge technologies, which could have significant benefits for those experiencing and those not yet diagnosed with PD.
With two FDA-cleared products — NeuroCap(TM) and NeuroEEG(TM) — BRSF is disrupting the EEG market by offering cost-effective, disposable solutions that have the ability to bridge the gap in access to neurological testing.
In diagnosing PD, a movement disorder specialist, a neurologist specializing in PD, observes tasks performed by the patient to make a diagnosis. There is currently no exact method of diagnosis but rather a series of tests and tasks that occur over a period of time that lead to an educated conclusion (https://ibn.fm/5aUJM).
There is an increase in need and a decrease in the number of those studying to become a neurologist, an estimated 19% shortage by 2025 (https://ibn.fm/to2MD). Access to care and availability of these much-needed appointments is decreasing. Take into account that a PD diagnosis is best made by a movement disorder specialist, and the gap increases even further.
“You have very long wait times to see a neurologist, especially for chronic diseases like dementia, and you have huge shortages of specialists to treat people with stroke,” says Dr. Lee Schwamm, a Harvard Medical School neurology professor. Schwamm says the shortfall could turn into a public emergency if society doesn’t act soon. “We need to build capacity now, because it takes 10 years to train a neurologist,” he notes.
The good news is that studies have found that EEGs may hold the key to a clearer diagnosis. According to a study published in eNeuro, the waveform shape that is detected with an EEG might be a biomarker for PD pathophysiology (https://ibn.fm/aRfro). A difference was found in PD patients who were on medication and those who were not. This provides the opportunity to diagnose PD and monitor the changes in the brain throughout the course of the disease, giving scientists more insight into how PD progresses.
The challenge becomes making sure that those with symptoms have access to an EEG and a skilled neurologist for analysis. That’s where Brain Scientific’s FDA-cleared NeuroCap comes into play.
The NeuroCap has clear advantages to its bulkier EEG counterpart. The bulkier version requires a skilled specialist to administer, comes with metal disks and wires, requires constant cleaning and sterilization, and takes up to 30 minutes to administer, not including prep or cleaning time. With the NeuroCap, any clinical personnel can apply the disposable headset in five minutes or less. This allows for EEGs to be administered in a almost any location, including the patient’s home or nursing homes, assisted living facilities or clinics. In addition, because the cap is disposable, there is no need to sanitize after each use; the device is also compatible with conventional EEG amplifiers. The data can be reviewed and evaluated through third-party software, reducing the need for a neurologist to be on site.
Brain Scientific is making significant strides in its mission to bridge the widening gap in neurological care. PD diagnosis is only one of many neurological issues that the company is tackling. BRSF is working on algorithms to detect neurological disorders, including epilepsy, dementia and pre-Alzheimer’s diagnosis.
For more information, visit the company’s website at www.BrainScientific.com.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.